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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
Primary
To assess the relative effectiveness and produce a clinically meaningful hierarchy of first-line uterotonic drugs for the treatment of
postpartum haemorrhage (PPH).
Secondary
To assess the relative risks and produce side effect hierarchies of first-line uterotonic drugs for the treatment of PPH.
B A C K G R O U N D
Description of the condition
An estimated 303,000 women died in childbirth worldwide in
2015 (Alkema 2016). This equates to a 1 in 180 global lifetime
risk of maternal death (WHO 2015). Postpartum haemorrhage
(PPH) is the leading contributor to maternal deaths, account-
ing for around 27% of all cases (Say 2014). Even when death is
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avoided, the risk of major maternal morbidity such as blood trans-
fusion or hysterectomy is substantial (Penny 2007; Carroll 2016).
The long-term sequelae of PPH can include anxiety, depression,
and post-traumatic stress disorder (Carroll 2016).
PPH is defined as blood loss in excess of 500 mL following birth
(WHO2012).Many clinicianswould identify a 500mLblood loss
as a tipping point for progression to treatment (Mavrides 2016).
However, because of the poor association of 500 mL loss with
morbidity, others use 1000 mL or even PPH-related morbidity
to define PPH (Kerr 2016). Indeed, many clinicians report that
they commence treatment as soon as they are unhappy with the
rate of bleeding, rather than wait for any specific volume of loss
(Hancock 2015).
The mainstay of management of PPH is to prevent it and, should
prevention fail, to treat it. A comparison between uterotonic drugs
to prevent PPH is covered by another Cochrane review and net-
work meta-analysis (Gallos 2015). A comparison between utero-
tonic drugs to treat PPH is the subject of this review.
TheWorld Health Organization (WHO) recommendation to use
intravenous oxytocin as a first-line treatment is based on moder-
ate-quality evidence, and recommendations to use ergometrine or
prostaglandins are based on low-quality evidence (WHO 2012).
The UK’s National Institute for Health and Care Excellence
(NICE) guidelines also highlight the lack of robust evidence to
guide recommendations (NICE 2014). Consequently, in the UK
there is a wide variation in the management of PPH, with several
drugs used for treatment (Al Wattar 2017). Hence, there is an
urgent need to define the most effective drug for the treatment of
PPH.
Description of the intervention
PPH treatment is characterised by interventions to remedy the
cardinal cause(s) of haemorrhage. It particularly seeks to improve
uterine tone, and if necessary to repair any trauma, to remove the
placenta andmembranes in entirety, and to correct the clotting cas-
cade (Coomarasamy 2016). In clinical practice uterotonic drugs
are administered to improve uterine tone as a primary factor, while
other issues are excluded or managed as secondary factors. Inter-
ventions such as surgery, embolization and/or compression have
been described, but this review will focus entirely on uterotonic
drugs because the relative treatment effects of these interventions
are particularly uncertain.
How the intervention might work
Uterotonic drugs work by increasing the contractility (tone) of the
uterus, thereby compressing the blood vessels of the myometrium
(smooth muscle tissue in the uterus) and reducing bleeding. Each
drug has its own unique side effect profile and mode of action,
although the end effect is increased uterine tone.
Oxytocin, a nine-amino-acid peptide, is widely regarded as the
gold standard treatment of PPH, although the optimal dose and
route of administration for treatment remain unclear (WHO
2012). Furthermore, there is clinical and laboratory evidence that
whilst the first dose of oxytocin is effective, repeated doses become
increasingly ineffective (Weeks 2015).
An analogue of oxytocin, carbetocin, which produces sustained
rather than rhythmic contraction of the uterus, is also used for the
treatment of PPH, but it has been evaluated largely for prevention
only (Su 2012).
Ergometrine is an ergot alkaloid that increases the muscle tone of
the uterus. It has long been used in both treatment and preven-
tion of PPH, although the optimum dose and route are debated
(Liabsuetrakul 2007). Syntometrine - a combination of oxytocin
and ergometrine - has been advocated in the treatment of PPH
for many years (Mavrides 2016).
Misoprostol is a synthetic analogue of prostaglandin E1 with
methylation at C16. The use of misoprostol to treat PPH is recog-
nised, although the optimum route and dosage is also a matter
of contention (Hofmeyr 2005). Carboprost is another synthetic
prostaglandin analogue of PGF2 with uterotonic properties, often
used in cases where oxytocin has already been used and a further
uterotonic is indicated (Bateman 2014).
Why it is important to do this review
Across the world, maternal mortality remains unacceptably high,
and excessive bleeding after childbirth is a leading cause. Although
maternal mortality risks are greatest in low-income settings, in re-
cent years a rise in the number of deaths from PPH in developed
healthcare settings serves to highlight that PPH is a global prob-
lem, requiring ongoing effort to find solutions (Mehrabadi 2013).
Active management of the third stage of labour may reduce the
amount of bleeding and related morbidity (WHO 2012; Begley
2015), but remains unlikely to completely prevent PPH, so the
need to identify effective treatment is urgent.
A Cochrane review has compared different uterotonic drugs for
treating PPH (Mousa 2014). Standard pair-wisemeta-analyses can
only compare those treatments that have been directly compared
in head-to-head trials. Standard pair-wise meta-analyses do not
allow ranking of the various drugs. In the absence of a single
high-quality, randomised controlled trial comparing all uterotonic
agents, significant uncertainty remains about which is the most
effective at treating PPH. In relation to a complex event such as
PPH, with several competing treatment options, not all of which
have been directly compared, a network meta-analysis may be
better able to allow for comparisons and conclusions about which
uterotonic drug is most effective.
A network meta-analysis simultaneously pools all the available
direct and indirect evidence on relative treatment effects, to achieve
a single coherent analysis (Caldwell 2005;Caldwell 2010). Indirect
evidence is obtained by inferring the relative effectiveness of two
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competing treatments through a common comparator. A network
meta-analysis produces estimates of the relative effects of each
treatment compared with every other in a network, even though
some pairs may not have been directly compared, and has the
potential to reduce the uncertainty in treatment effect estimates
(Caldwell 2010). It also enables calculation of the probability that
each treatment is the best for any given outcome, allowing ranking
of the various drugs. The proposed systematic review and network
meta-analysis is important; we will identify and rank first-line
uterotonic drugs for the treatment of PPH and demonstrate gaps
in the direct evidence to guide clinical decisionmaking and further
research.
O B J E C T I V E S
Primary
To assess the relative effectiveness and produce a clinically mean-
ingful hierarchy of first-line uterotonic drugs for the treatment of
postpartum haemorrhage (PPH).
Secondary
To assess the relative risks and produce side effect hierarchies of
first-line uterotonic drugs for the treatment of PPH.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomised controlled trials including cluster tri-
als of uterotonic drugs for the treatment of postpartum haemor-
rhage (PPH). Cross-over trials and quasi-randomised trials will be
excluded. The cross-over study design is inappropriate to investi-
gate the effectiveness of PPH treatment, and quasi-randomisation
rather than true randomisation brings an elevated risk of bias that
we wish to eliminate for the purpose of this review.
Types of participants
We will include studies involving participants delivering a baby
(live or stillborn) from 24 weeks of gestation with a diagnosis of
PPH within the first 24 hours (primary PPH). Studies with any
participants giving birth before 24 weeks of gestation or women
undergoing termination of pregnancy will be excluded.
Types of interventions
Studies of first-line uterotonic drugs administered systemically for
the treatment of primary PPH will be included. These drugs may
comprise oxytocin, ergot alkaloids, misoprostol, carbetocin or car-
boprost, or combinations of them. Systemic administration may
comprise sublingual, subcutaneous, intramuscular, rectal, inhaled,
nasal, oral or intravenous (both bolus and/or infusion) routes.
We will include studies comparing uterotonic drugs against other
uterotonic drugs or placebo. Studies comparing other interven-
tions including non-uterotonic drugs such as tranexamic acid will
be excluded.
Types of outcome measures
We will estimate the relative effects and ranking of the competing
interventions according to the following primary and secondary
outcomes.
Primary outcomes
• Number of participants with additional blood loss of more
than 500 mL after recruitment to cessation of active bleeding.
• Composite outcome of maternal death or severe morbidity
(e.g. hysterectomy, any organ dysfunction, transfer to higher
level of care, coagulopathy, shock as defined by trialists).
Secondary outcomes
• Number of participant deaths.*
• Number of participants requiring additional uterotonics.*
• Number of participants with additional blood loss of more
than 1000 mL after recruitment to cessation of active bleeding.*
• Number of participants having additional surgical
procedures (e.g. hysterectomy, balloon insertion, pack insertion,
arterial ligation, embolization and compression sutures).*
• Number of participants requiring blood transfusion or
other blood products.*
• Mean additional blood loss (mL).
• Change in haemoglobin measurements before and after
delivery (g/L).
• Number of participants experiencing side effects:
hyperthermia (temperature above 38°C), hypothermia
(temperature below 36°C), nausea, vomiting, hypertension,
headache, shivering, tachycardia, arrhythmia, diarrhoea and
abdominal pain.
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• Number of participants reporting a sense of wellbeing,
acceptability and satisfaction of the intervention.
• Number of participants breastfeeding on discharge.
(*denotes top five secondary outcomes of interest.)
Search methods for identification of studies
The following methods section of this protocol is based on a stan-
dard template used by Cochrane Pregnancy and Childbirth and
the recent protocol adaption for multiple interventions suggested
by Chaimani and colleagues (Chaimani 2017).
Electronic searches
We will search Cochrane Pregnancy and Childbirth’s Trials Regis-
ter by contacting their Information Specialist.
The Register is a database containing over 22,000 reports of con-
trolled trials in the field of pregnancy and childbirth. For full search
methods used to populate Pregnancy andChildbirth’s Trials Regis-
ter including the detailed search strategies for CENTRAL, MED-
LINE, Embase and CINAHL; the list of handsearched journals
and conference proceedings, and the list of journals reviewed via
the current awareness service, please follow this link to the edi-
torial information about Cochrane Pregnancy and Childbirth in
theCochrane Library and select the ‘Specialized Register ’ section
from the options on the left side of the screen.
Briefly, the Cochrane Pregnancy and Childbirth’s Trials Register
is maintained by their Information Specialist and contains trials
identified from:
1. monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL);
2. weekly searches of MEDLINE (Ovid);
3. weekly searches of Embase (Ovid);
4. monthly searches of CINAHL (EBSCO);
5. handsearches of 30 journals and the proceedings of major
conferences; and
6. weekly current awareness alerts for a further 44 journals
plus monthly BioMed Central email alerts.
Search results are screened by two people and the full text of all
relevant trial reports identified through the searching activities de-
scribed above is reviewed. Based on the intervention described,
each trial report is assigned a number that corresponds to a spe-
cific Pregnancy and Childbirth review topic (or topics), and is
then added to the Register. The Information Specialist searches
the Register for each review using this topic number rather than
keywords. This results in amore specific search set that will be fully
accounted for in the relevant review sections (Included, Excluded,
Awaiting Classification or Ongoing).
In addition, we will search ClinicalTrials.gov and the WHO In-
ternational Clinical Trials Registry Platform (ICTRP) for unpub-
lished, planned and ongoing trial reports using the search terms
described in Appendix 1.
Searching other resources
We will screen the reference lists of studies identified for inclu-
sion in the review, and seek to obtain relevant manuscripts not
retrieved by the methods described above. We will also seek to
obtain the full texts of studies retrieved as abstracts. In cases where
published study reports do not contain sufficient information to
determine eligibility for inclusion, or to extract the data required
for analysis, we will approach primary authors to obtain missing
details. In cases where the abstract has been published and the
author incommunicado, we will extract all relevant data from the
abstract. We will not apply any language or date restrictions when
considering manuscripts for inclusion in this review.
Data collection and analysis
The following methods section of this protocol is based on a stan-
dard template used by Cochrane Pregnancy and Childbirth.
Selection of studies
Two review authors will independently assess for inclusion all the
studies we identify as a result of the search strategy.We will resolve
any disagreement through discussionor, if required,wewill consult
a third person.
We will create a study flow diagram to map out the number of
records identified, included and excluded (Moher 2009).
Data extraction and management
We will design a form to extract data. For eligible studies, two
review authors will extract the data using the agreed form.We will
resolve discrepancies through discussion or, if required, we will
consult a third person. We will enter data into Review Manager
software (RevMan 2014) and into Microsoft Access and check for
accuracy.When information regarding any of the above is unclear,
wewill attempt to contact authors of the original reports to provide
further details. We will extract the following data.
Outcome data
We will extract primary and secondary outcomes listed above. All
relevant data will be extracted per trial arm.
Data on potential effect modifiers
Most prospective clinical studies of PPH have recruited women
at low risk of PPH, although most morbidity and mortality from
the condition occurs among those at high risk (e.g. emergency
caesareans, placental abruption, placenta praevia) (Weeks 2015).
It is therefore important to describe carefully the population of
each study and other effect modifiers, to identify the scope for
generalisability of the review findings as well as the research gaps.
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We will further extract data that may act as effect modifiers,
namely: gestational age; parity of the participants; mode of de-
livery; prior risk of PPH; uterotonic administration prior to en-
rolment; dosage; route of drug administration; study setting; co-
interventions such as tranexamic acid and uterine massage; and
randomisation unit.
Other data
Finally, we will extract the following other data: country or coun-
tries, in which the study was performed; year of publication; num-
ber of participants randomised; exclusion criteria; type of publi-
cation (full text, abstract or unpublished data); trial registration
reference; sufficient information to enable critical appraisal of the
risk of bias of each study, as described below.
Assessment of risk of bias in included studies
Two review authors will independently assess the risk of bias of
each study using the criteria outlined in the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011), modified as
appropriate to the context of this review, and described below. We
will resolve any disagreement by discussion or by involving a third
assessor.
(1) Random sequence generation (checking for possible
selection bias)
We will describe for each included study the method used to gen-
erate the allocation sequence in sufficient detail to allow an assess-
ment of whether it should produce comparable groups. We will
assess the method as:
• low risk of bias (any truly random process, e.g. random
number table; computer random number generator);
• high risk of bias (any non-random process, e.g. odd or even
date of birth; hospital or clinic record number); or
• unclear risk of bias.
(2) Allocation concealment (checking for possible selection
bias)
We will describe for each included study the method used to con-
ceal allocation to interventions prior to assignment and we will
assess whether intervention allocation could have been foreseen in
advance of, or during recruitment. We will assess the methods as:
• low risk of bias (e.g. telephone or central randomisation;
consecutively numbered sealed opaque envelopes);
• high risk of bias (open random allocation; unsealed or non-
opaque envelopes, alternation; date of birth); or
• unclear risk of bias (method unspecified).
(3.1) Blinding of participants and personnel (checking for
possible performance bias)
We will describe for each included study the methods used, if
any, to blind study participants and personnel from knowledge of
which intervention a participant received. We will consider that
studies are at low risk of bias if they were blinded, or if we judge
that the lack of blinding would be unlikely to affect results. We
will assess blinding separately for each primary outcome. We will
assess the methods as:
• low, high or unclear risk of bias for participants; or
• low, high or unclear risk of bias for personnel.
(3.2) Blinding of outcome assessment (checking for possible
detection bias)
We will describe for each included study the methods used, if any,
to blind outcome assessors and study participants from knowledge
of which intervention was received. We will assess blinding sepa-
rately for each primary outcome. We will assess methods used to
blind outcome assessment as low, high or unclear risk of bias.
(4) Incomplete outcome data (checking for possible attrition
bias due to the amount, nature and handling of incomplete
outcome data)
Wewill describe for each included study, and for each primary out-
come, the completeness of data including attrition and exclusions
from the analysis. We will state whether attrition and exclusions
were reported and the numbers included in the analysis at each
stage (compared with the total randomised participants), reasons
for attrition or exclusion where reported, and whether missing
data were balanced across groups or were related to outcomes.
We will assess methods as:
• low risk of bias (e.g. no missing outcome data; missing
outcome data balanced across groups or not exceeding 10% for
the primary outcomes of the review);
• high risk of bias (e.g. numbers or reasons for missing data
imbalanced across groups; ‘as treated’ analysis performed with
substantial departure from the numbers of participants allocated
to each group at randomisation or in excess of 10% for the
primary outcomes of the review); or
• unclear risk of bias (exclusions or attrition unreported).
(5) Selective reporting (checking for reporting bias)
We will describe for each included study any inconsistency be-
tween the prespecified study protocol (if available), the studymeth-
ods described in the study report, and the results listed in the study
report. We will assess the methods as:
• low risk of bias (where it is clear that all of the study’s
prespecified outcomes and all expected outcomes of interest to
the review have been reported);
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• high risk of bias (where not all prespecified outcomes have
been reported; one or more reported primary outcomes were not
prespecified; outcomes of interest are reported incompletely and
so cannot be used; or failure to report results of a key outcome
that would have been expected to have been included); or
• unclear risk of bias (prespecified study protocol
unavailable).
(6) Other bias (checking for bias due to problems not
covered by (1) to (5) above)
(6.1) The method used to measure blood loss could generate bias.
We will describe the method used and classify it as:
• low risk of other bias (objective measurement such as
weighing swabs, drapes, etc.);
• high risk of other bias (subjective measurement such as
visual or clinical estimation); or
• unclear risk of other bias (unspecified method of
measurement).
(6.2) The source of financial support for the study could generate
bias. We will describe the source of funding and classify it as:
• low risk of other bias (public funding or no external
funding);
• high risk of bias (funding from individuals or institutions
with material interests in the findings); or
• unclear risk of other bias (unspecified source of funding).
(6.3) We will describe for each included study any declared con-
flicts of interest and/or other important concerns about the risk of
bias, and classify these as:
• low risk of other bias (no conflicts of interest or other
concerns);
• high risk of bias (conflicts of interest that generate concern);
or
• unclear risk of other bias (uncertain influence of conflicts of
interest).
(7) Overall risk of bias
We will make explicit judgements about whether studies are at
high risk of bias, according to the criteria given in theCochrane
Handbook (Higgins 2011). With reference to (1) to (6) above,
we will assess the likely magnitude and direction of the bias and
whether we consider it is likely to impact on the findings. We
will explore the impact of the level of bias through undertaking
sensitivity analyses (see Sensitivity analysis).
Measures of treatment effect
Relative treatment effects
We will summarise the relative treatment effects of dichotomous
outcomes with risk ratios (RRs) and 95% confidence intervals
(CIs). We will summarise the relative treatment effects of out-
comes with continuous scales of measurement with mean differ-
ences (MDs). If different scales have been used we will use stan-
dardised mean differences (SMDs) with 95% CIs. In the event
of the target parameter being a change in a continuous measure,
such as change in haemoglobin, we will where possible account for
the within-patient correlation between baseline and postpartum
estimates (Dias 2013).
Relative treatment ranking
For each intervention we will estimate the ranking probabilities
of being at each possible rank. We will obtain a treatment hierar-
chy using the Surface Under the Cumulative RAnking curve (SU-
CRA) (Salanti 2011). Uncertainty intervals (95% CIs) around the
ranking of each treatment will be reported and considered when
interpreting the results. Each outcome will be evaluated to deter-
mine confidence in the output of the network meta-analysis as
described by Salanti and colleagues (Salanti 2014).
Unit of analysis issues
Cluster-randomised trials
Wewill include cluster-randomised trials in the analyses alongwith
individually randomised trials. We will adjust their standard errors
using the methods described in the Cochrane Handbook, with an
estimate of the intracluster correlation co-efficient (ICC) derived
from the trial (if possible), or (otherwise) from a similar trial or
froma study of a similar population (Higgins 2011). If we use ICCs
from other sources, we will report this and conduct sensitivity
analyses to investigate the effects of variations in the ICC. We
will consider it reasonable to combine the results if there is little
heterogeneity between the study designs and if the randomisation
unit could not plausibly affect the effects of the interventions.
However, we will perform sensitivity analyses to assess the validity
of such combination.
Cross-over trials
This type of trial is not appropriate for this intervention, and will
be excluded from the review.
Multi-arm trials
Multi-arm trials will be included and we will account for the corre-
lation between the effect sizes in the networkmeta-analysis. Multi-
arm studies will be treated as multiple independent comparisons
in pair-wise meta-analyses.
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Dealing with missing data
For included studies, we will note levels of attrition per primary
outcome (see also ’Incomplete outcome data’ in Assessment of
risk of bias in included studies). We will explore the impact of
including studies with high levels of missing data in the overall
assessment of treatment effect by using sensitivity analysis (see
Sensitivity analysis).
For all outcomes, we will carry out analyses, as far as possible,
on an intention-to-treat basis, i.e. we will attempt to include all
participants randomised to each group in the analyses, and all
participants will be analysed in the group to which they were
allocated, regardless of whether or not they received the allocated
intervention.
Assessment of transitivity across treatment
comparisons
We will assess the assumption of transitivity by comparing the
distribution of potential effect modifiers across the different pair-
wise comparisons. We consider that the assumption of transitivity
will be likely to hold given that: the common treatment used to
compare different uterotonics indirectly is likely to be similar in
different trials (e.g. oxytocin is administered in a similar way in
studies of oxytocin versus misoprostol as it is in studies of oxytocin
versus carbetocin); and pair-wise comparisons are unlikely to differ
in respect of the distributionof effectmodifiers (e.g. all trial designs
and characteristics are similar).
The assumption of transitivity will be evaluated by comparing
the clinical and methodological characteristics of sets of studies
grouped by treatment comparisons.
Assessment of reporting biases
In view of the difficulty of detecting and correcting for publication
bias and other reporting biases, we will aim to minimise their
potential impact by ensuring a comprehensive search for eligible
studies and by being alert for duplication of data. If 10 or more
studies are included in the network meta-analysis, we will use a
comparison-adjusted funnel plot to explore the possibility of small
study effects (a tendency for estimates of the intervention effect to
be more beneficial in smaller studies) (Chaimani 2013).
Data synthesis
Methods for direct treatment comparisons
Wewill perform standard pair-wisemeta-analyses using a random-
effects model in STATA for every treatment with at least two
studies (DerSimonian 1986).
Methods for network meta-analysis
We will extract the sample size and number of outcome events
per trial arm, to be used in the Stata network suite of commands
(White 2015). Once extracted, we will set up the data using the
augmented format, where all treatments are comparedwith a refer-
ence treatment, and studies without the reference treatment have
a reference treatment arm created with a small amount of data
(White 2011). The augmentation process using arm-based values
will calculate the risk estimates of the comparisons with reference
treatment and their variances and covariances (White 2015).
Subgroup analysis and investigation of heterogeneity
Assumptions when estimating heterogeneity
In standard pair-wise meta-analyses we will assume different het-
erogeneity for each pair-wise comparison. In network meta-anal-
ysis we will assume a common estimate for heterogeneity across
the different comparisons.
Measures and tests for heterogeneity
Wewill assess statistically the presence of heterogeneitywithin each
pair-wise comparison using the I2 statistic and its 95% CI that
measures the percentage of variability that cannot be attributed
to random error. We will assess statistically the presence of het-
erogeneity in the entire network based on the magnitude of the
heterogeneity variance parameter (T2) estimated from the multi-
variate meta-analysis model. The magnitude of the heterogeneity
variance will be compared to empirical distributions for dichoto-
mous and continuous variables (Turner 2012; Rhodes 2015).
Assessment of statistical inconsistency
The statistical agreement between various sources of evidence in a
network of interventions should be evaluated by global and local
approaches in tandemwith the evaluation of clinical homogeneity.
Local approaches for evaluation inconsistency
To evaluate the presence of inconsistency locally we will use the
node-splitting approach. The node-splitting technique will allow
two distinct components - direct evidence from direct compar-
isons or multi-arm trials and indirect evidence based on the re-
maining information (Dias 2010). The technique will be applied
to all comparisons in the network and allow generation of graph-
ics clearly showing the difference between combined information,
direct and indirect comparisons.
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Global approaches for evaluation inconsistency
To evaluate consistency in the entire network simultaneously we
will use the ’design by treatment’ interaction model as described
by Higgins 2012, which will be implemented in STATA. This
method accounts for different sources of inconsistency that can
occur when studies with different designs (two-arm trials versus
three-arm trials) give different results, as well as for disagreement
between direct and indirect evidence. Using this approach, we will
infer the presence of inconsistency from any source in the entire
network based on a Chi2 test.
Investigation of heterogeneity and inconsistency
If we find important heterogeneity and/or inconsistency, we will
investigate the possible sources of such anomalies in respect of both
primary outcomes and secondary outcomes. If sufficient studies
are available, we will perform subgroup analyses by using the fol-
lowing factors as possible sources of inconsistency and/or hetero-
geneity.
• Population: mode of delivery; prior PPH risk (high or low)
and setting (hospital delivery or community delivery including
home birth).
• Intervention: dosage; route.
• Randomisation unit: cluster versus individual.
• Funding source: risk of bias.
• Methods of blood loss measurement: risk of bias.
• Overall risk of bias: studies will be ranked ’low risk of bias’
if they are double-blinded, and have allocation concealment with
less than 10% loss to follow up. Studies with assessor blinding
and less than 10% loss to follow up will be ranked ’intermediate
risk of bias’. Studies with no blinding or more than 10% loss to
follow up will be ranked as ’high risk of bias’.
If these subgroup analyses do explain the heterogeneity/inconsis-
tency we will note that the results should be treated with caution.
Subgroup analysis
Regardless of heterogeneity and/or inconsistency, in respect of pri-
mary outcomes we will perform the following subgroup analyses
by evaluating the relative effects and assessment of model fit.
• Mode of delivery (vaginal versus caesarean delivery).
• Prior PPH risk (low versus high risk).
• Setting (hospital versus community births).
• Intervention: dosage and route.
• Uterotonic administration prior to enrolment.
• Co-interventions (e.g. tranexamic acid, uterine massage).
Sensitivity analysis
For the primary outcomeswewill perform the following sensitivity
analyses, as described previously.
• Overall risk of bias.
• Funding source.
• Objective versus subjective assessment of blood loss.
• Randomisation unit (cluster versus individual).
Differences will be assessed by evaluating the relative effects and
assessment of model fit.
‘Summary of findings’ table
We will assess the quality of evidence using the GRADE approach
outlined by Salanti and colleagues in order to assess the quality
of the body of evidence relating to the primary outcomes for all
comparisons (Salanti 2014). In order to create the ‘Summary of
findings’ tables we will use GRADEpro Guideline Development
Tool to import data from Revman 5 (RevMan 2014). We will use
the GRADE approach to report the intervention effect for each
of the above outcomes.
A C K N OW L E D G E M E N T S
Ammalife contributed to funding this review.
TheWorld Health Organization, William R Parry-Smith, Ioannis
D Gallos, Helen M Williams, Mubashir Angolkar, Malcolm J
Price, Aurelio Tobias, Zarko Alfirevic, Andrew Weeks, G Justus
Hofmeyr and Arri Coomarasamy retain copyright and all other
rights in their respective contributions to the manuscript of this
review as submitted for publication.
As part of the prepublication editorial process, this protocol has
been commented on by five peers (an editor and four referees
who are external to the editorial team), a member of Cochrane
Pregnancy and Childbirth’s international panel of consumers and
the Group’s Statistical Adviser.
This project was supported by the National Institute for
Health Research (NIHR), via Cochrane Infrastructure funding
to Cochrane Pregnancy and Childbirth. The views and opinions
expressed herein are those of the authors and do not necessarily
reflect those of the Systematic Reviews Programme, NIHR, Na-
tional Health Service or the Department of Health.
8First-line uterotonics for treating postpartum haemorrhage: a systematic review and network meta-analysis (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
R E F E R E N C E S
Additional references
Al Wattar 2017
Al Wattar B, Tamblyn JA, Parry-Smith W, Prior M, Van
Der Nelson H. Management of obstetric postpartum
hemorrhage: a national service evaluation of current
practice in the UK. Risk Management and Healthcare Policy
2017;10:1–6. [DOI: 10.2147/RMHP.S121737]
Alkema 2016
Alkema L, Chou D, Hogan D, Zhang S, Moller AB,
Gemmill A, et al. Global, regional, and national levels and
trends in maternal mortality between 1990 and 2015, with
scenario-based projections to 2030: a systematic analysis
by the UN Maternal Mortality Estimation Inter-Agency
Group. Lancet 2016;387(10017):462–74.
Bateman 2014
Bateman BT, Tsen LC, Liu J, Butwick AJ, Huybrechts KF.
Patterns of second-line uterotonic use in a large sample of
hospitalizations for childbirth in the United States: 2007-
2011. Anesthesia & Analgesia 2014;119(6):1344–9.
Begley 2015
Begley CM, Gyte GML, Devane D, McGuire W,
Weeks A. Active versus expectant management for
women in the third stage of labour. Cochrane Database
of Systematic Reviews 2015, Issue 3. [DOI: 10.1002/
14651858.CD007412.pub4]
Caldwell 2005
Caldwell DM, Ades AE, Higgins JP. Simultaneous
comparison of multiple treatments: combining direct and
indirect evidence. BMJ 2005;331:897–900.
Caldwell 2010
Caldwell DM, Welton NJ, Ades AE. Mixed treatment
comparison analysis provides internally coherent treatment
effect estimates based on overviews of reviews and can reveal
inconsistency. Journal of Clinical Epidemiology 2010;63:
875–82.
Carroll 2016
Carroll M, Daly D, Begley CM. The prevalence of
women’s emotional and physical health problems
following a postpartum haemorrhage: a systematic review.
BMC Pregnancy Childbirth 2016;16:261. [PUBMED:
PMC5011962]
Chaimani 2013
Chaimani A, Higgins JPT, Mavridis D, Spyridonos P,
Salanti G. Graphical tools for network meta-analysis in
STATA. PLoS ONE 2013;8(10):e76654. [DOI: 10.1016/
j.jclinepi.2016.11.015]
Chaimani 2017
Chaimani A, Caldwell DM, Li T, Higgins JPT, Salanti
G. Additional considerations are required when preparing
a protocol for a systematic review with multiple
interventions. Journal of Clinical Epidemiology 2017;83:
65–74. [PUBMED: 28088593]
Coomarasamy 2016
Steer P. Surgical management of massive obstetric
hemorrhage from the uterus, cervix, or vagina. In:
Coomarasamy A, Shafi M, Davila G, Chan K editor
(s). Gynecologic and Obstetric Surgery: Challenges and
Management Options. 1st Edition. Vol. 1, Chichester:
Wiley Blackwell, 2016:470–6. [9780470657614]
DerSimonian 1986
DerSimonian R, Laird N. Meta-analysis in clinical trials.
Controlled Clinical Trials 1986;7(3):177–88.
Dias 2010
Dias S, Welton NJ, Caldwell DM, Ades AE. Checking
consistency in mixed treatment comparison meta-analysis.
Statistics in Medicine 2010;29:932–44.
Dias 2013
Dias S, Sutton AJ, Ades AE, Welton NJ. Evidence synthesis
for decision making 2: a generalized linear modeling
framework for pairwise and network meta-analysis of
randomized controlled trials. Medical Decision Making
2013;33(5):607–17.
Gallos 2015
Gallos ID, Williams HM, Price MJ, Merriel A, Gee
H, Lissauer D, et al. Uterotonic agents for preventing
postpartum haemorrhage: a network meta-analysis.
Cochrane Database of Systematic Reviews 2015, Issue 5.
[DOI: 10.1002/14651858.CD011689]
Hancock 2015
Hancock A, Weeks AD, Lavender T. Is accurate and reliable
blood loss estimation the ’crucial step’ in early detection
of postpartum haemorrhage: an integrative review of the
literature. BMC Pregnancy and Childbirth 2015;28(15):
230.
Higgins 2011
Higgins JPT, Green S, editors. Cochrane Handbook
for Systematic Reviews of Interventions Version 5.1.0
(updated March 2011). The Cochrane Collaboration,
2011. Available from handbook.cochrane.org.
Higgins 2012
Higgins J, Jackson D, Barrett J, Lu G, Ades A, White I.
Consistency and inconsistency in network meta-analysis:
concepts and models for multi-arm studies. Research
Synthesis Methods 2012;3(2):98–110.
Hofmeyr 2005
Hofmeyr GJ, Walraven G, Gülmezoglu AM, Maholwana
B, Alfirevic Z, Villar J. Misoprostol to treat postpartum
haemorrhage: a systematic review. BJOG: an international
journal of obstetrics and gynaecology 2005;112:547–53.
Kerr 2016
Kerr R, Eckert LO, Winikoff B, Durocher J, Meher S,
Fawcus S, et al. Postpartum haemorrhage: case definition
and guidelines for data collection, analysis, and presentation
of immunization safety data. Vaccine 2016;34(49):6102–9.
[DOI: 10.1016/j.vaccine.2016.03.039]
9First-line uterotonics for treating postpartum haemorrhage: a systematic review and network meta-analysis (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Liabsuetrakul 2007
Liabsuetrakul T, Choobun T, Peeyananjarassri K, Islam
QM. Prophylactic use of ergot alkaloids in the third stage of
labour. Cochrane Database of Systematic Reviews 2007, Issue
2. [DOI: 10.1002/14651858.CD005456.pub2]
Mavrides 2016
Mavrides E, Allard S, Chandraharan E, Collins P, Green L,
Hunt BJ, et al. Prevention and management of postpartum
haemorrhage. BJOG: an international journal of obstetrics
and gynaecology 2016;124:e106–e149. [DOI: 10.1111/
1471-0528.14178]
Mehrabadi 2013
Mehrabadi A, Hutcheon JA, Lee L, Kramer MS, Liston RM,
Koseph KS. Epidemiological investigation of a temporal
increase in atonic postpartum haemorrhage: a population-
based retrospective cohort study. BJOG: an international
journal of obstetrics and gynaecology 2013;120(7):853–62.
Moher 2009
Moher D, Liberati A, Tetzlaff J, Altman DG, the PRISMA
Group. Preferred reporting items for systematic reviews
and meta-analyses: the PRISMA statement. PLoS Medicine
2009;6(7):e1000097.
Mousa 2014
Mousa HA, Blum J, Abou El Senoun G, Shakur H, Alfirevic
Z. Treatment for primary postpartum haemorrhage.
Cochrane Database of Systematic Reviews 2014, Issue 2.
[DOI: 10.1002/14651858.CD003249.pub3]
NICE 2014
National Institute for Health and Care Excellence.
Intrapartum care: care of healthy women and their babies
during childbirth. www.nice.org.uk/guidance/cg190 2014.
Penny 2007
Penney G, Brace V. Near miss audit in obstetrics. Current
Opinion in Obstetrics and Gynaecology 2007;19:145–50.
RevMan 2014 [Computer program]
Nordic Cochrane Centre, The Cochrane Collaboration.
Review Manager (RevMan). Version 5.3. Copenhagen:
Nordic Cochrane Centre, The Cochrane Collaboration,
2014.
Rhodes 2015
Rhodes KM, Turner RM, Higgins JPT. Predictive
distributions were developed for the extent of heterogeneity
in meta-analyses of continuous outcome data. Journal of
Clinical Epidemiology 2015;68(1):52–60. [DOI: 10.1016/
j.jclinepi.2014.08.012]
Salanti 2011
Salanti G, Ades AE, Ioannidis JP. Graphical methods and
numerical summaries for presenting results from multiple-
treatment meta-analysis: an overview and tutorial. Journal
of Clinical Epidemiology 2011;64(2):163–71.
Salanti 2014
Salanti G, Del Giovane C, Chaimani A, Caldwell DM,
Higgins JPT. Evaluating the quality of evidence from a
network meta-analysis. PloS One 2014;9(7):e99682. [DOI:
10.1371/journal.pone.0099682]
Say 2014
Say L, Chou D, Gemmill A, Tunçalp Ö, Moller AB, Daniels
J, et al. Global causes of maternal death: a WHO systematic
analysis. Lancet Global Health 2014;2(6):e323–333.
Su 2012
Su LL, Chong YS, Samuel M. Carbetocin for preventing
postpartum haemorrhage. Cochrane Database of
Systematic Reviews 2012, Issue 4. [DOI: 10.1002/
14651858.CD005457.pub4]
Turner 2012
Turner RM, Davey J, Clarke MJ, Thompson SG, Higgins
JP. Predicting the extent of heterogeneity in meta-analysis,
using empirical data from the Cochrane Database of
Systematic Reviews. International Journal of Epidemiology
2012;41(3):818–27. [DOI: 10.1093/ije/dys041]
Weeks 2015
Weeks AD, Neilson JP. Rethinking our approach to
postpartum haemorrhage and uterotonics. BMJ 2015;8:
h3251.
White 2011
White IR. Multivariate random-effects meta-regression:
updates to mvmeta. Stata Journal 2011;11(2):255–70.
White 2015
White IR. Network meta-analysis. Stata Journal 2015;15
(4):951–85.
WHO 2012
World Health Organization. Recommendation for the
prevention and treatment of postpartum haemorrhage.
WHO 2012.
WHO 2015
WHO, UNICEF, UNFPA, World Bank Group and the
United Nations Population Division. Trends in Maternal
Mortality 1990 to 2015. WHO 2015.
∗ Indicates the major publication for the study
10First-line uterotonics for treating postpartum haemorrhage: a systematic review and network meta-analysis (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A P P E N D I C E S
Appendix 1. Search terms for ClinicalTrials.gov and ICTRP
ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform (ICTRP)
Third stage AND labo(u)r AND oxytocin
Third stage AND labo(u)r AND misoprostol
Third stage AND labo(u)r AND carbetocin
Third stage AND labo(u)r AND ergometrine
Third stage AND labo(u)r AND carboprost









h(a)emorrhage AND postpartum AND ergometrine
h(a)emorrhage AND postpartum AND oxytocin
h(a)emorrhage AND postpartum AND carbetocin
h(a)emorrhage AND postpartum AND misoprostol
h(a)emorrhage AND postpartum AND syntometrine
h(a)emorrhage AND postpartum AND carboprost
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